Stockscreener 앱 받기
254.40
2.28%
5.66
시간 외 거래:
254.40
전일 마감가:
$248.74
열려 있는:
$253.08
하루 거래량:
1.20M
Relative Volume:
0.92
시가총액:
$35.48B
수익:
$2.12B
순이익/손실:
$-309.19M
주가수익비율:
-111.38
EPS:
-2.2841
순현금흐름:
$93.57M
1주 성능:
+11.05%
1개월 성능:
+4.03%
6개월 성능:
+60.31%
1년 성능:
+49.30%
1일 변동 폭
$250.26
$256.36
1주일 범위
$225.82
$256.36
52주 변동 폭
$125.38
$256.36
Natera Inc Stock (NTRA) Company Profile
명칭
Natera Inc
전화
650-249-9090
주소
13011 MCCALLEN PASS, AUSTIN, CA
NTRA을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
NTRA
Natera Inc
|
254.40 | 34.69B | 2.12B | -309.19M | 93.57M | -2.2841 |
|
TMO
Thermo Fisher Scientific Inc
|
617.15 | 233.21B | 43.74B | 6.58B | 6.11B | 17.31 |
|
DHR
Danaher Corp
|
235.57 | 167.12B | 24.27B | 3.50B | 5.02B | 4.8589 |
|
IDXX
Idexx Laboratories Inc
|
714.55 | 56.44B | 4.17B | 1.03B | 940.22M | 12.61 |
|
A
Agilent Technologies Inc
|
147.81 | 41.84B | 6.95B | 1.30B | 1.15B | 4.5696 |
|
IQV
Iqvia Holdings Inc
|
244.29 | 40.96B | 15.90B | 1.28B | 2.21B | 7.2842 |
Natera Inc Stock (NTRA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-02 | 재개 | Morgan Stanley | Overweight |
| 2025-10-27 | 업그레이드 | BNP Paribas Exane | Underperform → Neutral |
| 2025-09-22 | 재개 | Wells Fargo | Equal Weight |
| 2025-03-13 | 개시 | RBC Capital Mkts | Outperform |
| 2025-01-23 | 개시 | Barclays | Overweight |
| 2024-06-03 | 재개 | Jefferies | Buy |
| 2024-04-08 | 재개 | Craig Hallum | Buy |
| 2024-02-20 | 다운그레이드 | Raymond James | Strong Buy → Outperform |
| 2023-12-29 | 재확인 | BTIG Research | Buy |
| 2023-12-14 | 개시 | Guggenheim | Buy |
| 2023-12-13 | 개시 | Wolfe Research | Outperform |
| 2023-11-13 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2023-09-28 | 개시 | Bernstein | Mkt Perform |
| 2023-07-05 | 재개 | JP Morgan | Overweight |
| 2023-05-05 | 개시 | UBS | Buy |
| 2023-01-18 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2022-08-25 | 개시 | Credit Suisse | Outperform |
| 2022-04-25 | 개시 | Stephens | Overweight |
| 2022-03-08 | 개시 | Goldman | Buy |
| 2022-01-06 | 재개 | Piper Sandler | Overweight |
| 2021-10-15 | 재개 | Cowen | Outperform |
| 2021-06-15 | 개시 | Raymond James | Mkt Perform |
| 2021-05-25 | 개시 | Wells Fargo | Overweight |
| 2021-01-28 | 개시 | Truist | Buy |
| 2020-10-08 | 개시 | BTIG Research | Buy |
| 2020-09-28 | 개시 | Morgan Stanley | Overweight |
| 2020-09-17 | 개시 | SVB Leerink | Outperform |
| 2020-06-10 | 재개 | Piper Sandler | Overweight |
| 2020-05-07 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2018-10-05 | 개시 | JP Morgan | Neutral |
| 2018-07-05 | 재확인 | Piper Jaffray | Overweight |
| 2017-08-07 | 재확인 | Morgan Stanley | Overweight |
| 2016-11-10 | 재확인 | The Benchmark Company | Buy |
| 2016-05-23 | 재확인 | The Benchmark Company | Buy |
| 2016-05-11 | 재확인 | The Benchmark Company | Buy |
| 2016-04-19 | 개시 | The Benchmark Company | Buy |
| 2015-09-28 | 업그레이드 | Wedbush | Neutral → Outperform |
| 2015-08-14 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2015-08-04 | 개시 | Robert W. Baird | Outperform |
| 2015-07-27 | 개시 | Morgan Stanley | Equal-Weight |
| 2015-07-27 | 개시 | Piper Jaffray | Overweight |
| 2015-07-27 | 개시 | Wedbush | Neutral |
모두보기
Natera Inc 주식(NTRA)의 최신 뉴스
Why Natera’s Stock Is Sliding Despite Bullish Outlook - TipRanks
Natera (NTRA) announces publication of findings from randomized, phase III CALGB (Alliance)/SWOG 80702 study - MSN
Trade Tracker: Stephanie Link sells Eaton and buys more Zoetis, Natera - CNBC
Exelixis and Natera stocks rise on colorectal cancer trial collaboration - Investing.com
Exelixis, Natera to Collaborate on Phase 3 Colorectal Cancer Trial - MarketScreener
Insiders At Natera Sold US$47m In Stock, Alluding To Potential Weakness - Yahoo Finance
Citigroup Initiates Buy Rating on Natera (NTRA) with $300 Price Target | NTRA Stock News - GuruFocus
Exelixis and Natera to collaborate on MRD-guided cancer trial By Investing.com - Investing.com Australia
Exelixis and Natera to Collaborate on STELLAR-316, a Phase 3 Pivotal Trial of Zanzalintinib for Patients with Colorectal Cancer - Yahoo Finance
Natera: Leading MRD Position, Expanding Margins, and Premium Valuation Support Buy Rating and $300 Target - TipRanks
Natera Inc: President Moshkevich sells $675k in stock By Investing.com - Investing.com South Africa
Natera Inc: President Moshkevich sells $675k in stock - Investing.com India
Natera Inc stock hits all-time high at 247.0 USD - Investing.com
Expanded Fetal Test and Stronger ALTAIR Signal Could Be A Game Changer For Natera (NTRA) - simplywall.st
Natera Presents Updated Analyses From ALTAIR Clinical Trial at ASCO GI - The AI Journal
NTRA Gains Momentum as Guggenheim Raises Price Target to $270 | - GuruFocus
New prenatal blood test flags 21 inherited diseases with high accuracy - Stock Titan
Is Natera (NASDAQ:NTRA) A Risky Investment? - 富途牛牛
Natera (NASDAQ:NTRA) Upgraded at Zacks Research - MarketBeat
Exploring 3 High Growth Tech Stocks In The US Market - simplywall.st
Calamos Advisors LLC Has $930,000 Holdings in Natera, Inc. $NTRA - MarketBeat
Responsive Playbooks and the NTRA Inflection - Stock Traders Daily
Medical stock hovers near buy point after 46% gain - MSN
Ninety One UK Ltd Sells 218,812 Shares of Natera, Inc. $NTRA - MarketBeat
Allspring Global Investments Holdings LLC Sells 47,131 Shares of Natera, Inc. $NTRA - MarketBeat
Miami man arrested in nearly $1 million theft from tech company he worked for: Cops - NBC 6 South Florida
Natera (NTRA) Announces Publication of Findings from Randomized, Phase III CALGB (Alliance)/SWOG 80702 Study - Finviz
Miami man accused of stealing nearly $1 million from 2 South Florida businesses - WPLG Local 10
Natera, Inc. (NASDAQ:NTRA) Short Interest Update - MarketBeat
Natera CFO sells shares worth $7.76 million - MSN
Medical Stock Hovers Near Buy Point After 46% Gain - Investor's Business Daily
Reproductive Genetics Market Size to Reach USD 16.67 Billion in 2032 Amid Increasing Demand for Genetic Testing - GlobeNewswire Inc.
Analysts Are Bullish on These Healthcare Stocks: Natera (NTRA), Immunome (IMNM) - The Globe and Mail
Cwm LLC Increases Stake in Natera, Inc. $NTRA - MarketBeat
Vontobel Holding Ltd. Increases Stock Position in Natera, Inc. $NTRA - MarketBeat
Natera is Transforming Patient Care Using AI - Amazon Web Services (AWS)
Natera: Is Signatera’s Momentum About to Accelerate Again as Biomarker Laws Expand State by State? - Smartkarma
Natera, Inc. $NTRA Shares Bought by SWS Partners - MarketBeat
Is Natera’s 486% Three Year Surge Still Justified by Its Fundamentals? - Yahoo Finance
3 Reasons We’re Fans of Natera (NTRA) - Barchart.com
J.P. Morgan Lifts Natera, Inc. (NTRA) Target on Signatera Momentum - Finviz
Natera co-founder Sheena Jonathan sells $338913 in stock By Investing.com - Investing.com Nigeria
Natera co-founder Sheena Jonathan sells $338913 in stock - Investing.com
Canaccord Genuity Maintains Natera (NTRA) Buy Recommendation - Nasdaq
Natera, Inc. (NTRA) Stock Analysis: Evaluating Growth Potential Amid Robust Revenue Gains - DirectorsTalk Interviews
Natera (NTRA): Revisiting Valuation After New JAMA Oncology Data on Signatera’s Colorectal Cancer Benefit - simplywall.st
Natera (NASDAQ:NTRA) Price Target Raised to $285.00 - MarketBeat
Natera to Participate in the 44th Annual J.P. Morgan Healthcare Conference - marketscreener.com
Natera Inc (NTRA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.96%
1.56%
자본화:
|
볼륨(24시간):